WHAT IS INTRADISCAL STEM CELL THERAPY?
Intradiscal stem cell therapy, also known as intervertebral joint therapy, or intervertebral disc therapy, is a novel way to treat different disc pathologies and is the only procedure that regenerates discs in the spine. This procedure makes it possible to avoid complications associated with surgical procedures. When necessary, adjacent structures such as facet joints, sacroiliac joints, and surrounding nerve roots, are treated. Intradiscal stem cell therapy does not treat the spinal cord.
BENEFITS OF INTRADISCAL STEM CELL THERAPY
Patients who received intradiscal stem cell therapy indicate that they are very happy with the results. the outcomes become apparent over a 6-month period following the treatment. There are four (4) major benefits that you can expect from intradiscal stem cell therapy. These include:
- Significant and long-term relief from back pain;
- Increase in function and range of motion;
- Increase in the disc’s water content;
- Low complication rate.
These results are not guaranteed and may vary depending on the patient’s health condition and lifestyle.
WHO SHOULD CONSIDER THIS PROCEDURE?
You should consider this type of procedure if you have:
- Chronic back or neck pain
- Bulging, ruptured or herniated discs
- Degenerative disc disease
- Injured or diseased spinal nerve roots
- Sacroiliac degeneration
- Facet degeneration
Intradiscal stem cell therapy is an option for people who:
- Are considering surgery for their back problems
- Have been refused for surgery for their back problems
- Take opioids for their back problems
- Had back surgery
PREPARATION FOR THE PROCEDURE
- Eat normally and drink a lot of water the day before and the day of the procedure;
- Strengthen core muscles to protect the treated area;
- Additional guidelines will be given to you 4 weeks prior to your procedure.
A randomized control trial was conducted with patients who had clinically determined single level disc pain and degeneration (Pfirrmann III to VI). Patients received a single injection of proprietary allogeneic low-dose MSCs. After 12 months, almost 70% of the group showed greater than 50% reduction in VAS score (pain level). The group of patients reported a 15-point mean improvement in function (35% reduction on the Oswestry Disability Index [ODI]) and no further treatment intervention. Results of data analysis demonstrated that after 24 months, almost 50% of the group achieved minimal or no residual pain (VAS score is equal or less than 20).
Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of the Phase 3 Program at JP Morgan Healthcare Conference, January 2015.
On a case-by-case basis, intradiscal stem cell therapy may be covered by auto injury insurance (MVA) or worker’s injury insurance (WSIB). However, this treatment is not covered by other insurance companies, including OHIP.
If you are interested in finding out if Intradiscal Stem Cell Therapy can benefit you or someone you know, please contact us.